Efficacy of Ventavis Used in Real-life Setting.
The Efficacy of Inhaled Iloprost in Patients Treated Within the "Pulmonary Arterial Hypertension Therapeutic Programme".
Lead Sponsor: Bayer
This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis.
Typical clinical measures and quality of life will be prospectively followed in 12 months period.
|Start Date||August 5, 2010|
|Completion Date||September 22, 2016|
|Primary Completion Date||April 28, 2016|
Intervention Type: Drug
Intervention Name: Inhaled iloprost (Ventavis, BAYQ6256)
Description: Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
Arm Group Label: Group 1
Sampling Method: Probability Sample
Inclusion Criteria: - Pulmonary arterial hypertension in WHO functional class III or IV - Age 18+ - Patients newly treated with Ventavis or switched from sildenafil Exclusion Criteria: - Retrospective documentation is not allowed
- Pulmonary arterial hypertension in WHO functional class III or IV
- Age 18+
- Patients newly treated with Ventavis or switched from sildenafil
- Retrospective documentation is not allowed
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
|Has Expanded Access||No|
Label: Group 1
Description: Drug (incl. Placebo)
|Study Design Info||
Observational Model: Cohort
Time Perspective: Prospective